Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Excalipoint Therapeutics and DP Technology have partnered to develop an agentic…
Nucleai-University of Glasgow Partnership Expands Spatial AI Platform | Lucid Diligence Brief
Nucleai broadened its University of Glasgow collaboration to expand academic…
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Warburg Pincus to acquire control of PANTHERx Rare, backing expansion of the…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
Insilico Takeda AI Drug Discovery Deal | Lucid Diligence Brief
Insilico and Takeda test whether Pharma.AI can convert discovery speed into…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
Merck KGaA Bio-Techne Deal | Lucid Diligence Brief
Merck KGaA’s US$11.3bn Bio-Techne acquisition tests workflow depth, integration…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
LabGenius expands validation of its EVA antibody-discovery platform through a…